Keap1 loss promotes Kras-driven lung cancer and results in dependence on glutaminolysis

Treating KRAS-mutant lung adenocarcinoma (LUAD) remains a major challenge in cancer treatment given the difficulties associated with directly inhibiting the KRAS oncoprotein. One approach to addressing this challenge is to define mutations that frequently co-occur with those in KRAS, which themselve...

Full description

Bibliographic Details
Main Authors: Sayin, Volkan I. (Author), Singh, Simranjit X. (Author), LeBoeuf, Sarah E. (Author), Karakousi, Triantafyllia R. (Author), Martinez, Britney (Author), Bronson, Roderick T. (Author), Prigge, Justin R. (Author), Schmidt, Edward E. (Author), Thomas, Craig J. (Author), Goparaju, Chandra (Author), Davies, Angela (Author), Dolgalev, Igor (Author), Heguy, Adriana (Author), Allaj, Viola (Author), Poirier, John T. (Author), Moreira, Andre L. (Author), Rudin, Charles M. (Author), Pass, Harvey I. (Author), Papagiannakopoulos, Thales (Author), Davidson, Shawn M. (Contributor), Bauer, Matthew R. (Contributor), Ellis, Donald Christian (Contributor), Bhutkar, Arjun (Contributor), Sanchez-Rivera, Francisco Javier (Contributor), Subbaraj, Lakshmipriya (Contributor), Vander Heiden, Matthew G. (Contributor), Jacks, Tyler E. (Contributor), Romero, Rodrigo,Ph. D.Massachusetts Institute of Technology (Author)
Other Authors: Massachusetts Institute of Technology. Department of Biology (Contributor), Koch Institute for Integrative Cancer Research at MIT (Contributor), Romero, Rodrigo (Contributor)
Format: Article
Language:English
Published: Nature Publishing Group, 2018-06-22T19:12:01Z.
Subjects:
Online Access:Get fulltext